IGF-1R IS A PREDICTIVE BIOMARKER FOR EGFR TKI (GEFITINIB) RESISTANCE IN NON-SMALL CELL LUNG CANCER USING IHC AND AQUA TECHNOLOGY

被引:0
|
作者
Kato, Yasufumi [1 ]
Wynes, Murry W. [1 ]
Mascaux, Celine [1 ]
Asuncion, Bernadette G. Reyna [1 ]
Cindy Tran [1 ]
Yoshida, Koichi [2 ]
Matsubayashi, Jun [3 ]
Ohira, Tatsuo [2 ]
Furukawa, Kinya [4 ]
Nagao, Toshitaka [3 ]
Ikeda, Norihiko [2 ]
Hirsch, Fred R. [5 ]
机构
[1] Univ Colorado Denver, Div Med Oncol, Denver, CO USA
[2] Tokyo Med Univ, Div Thorac Surg, Tokyo 1608402, Japan
[3] Tokyo Med Univ, Div Anat Pathol, Tokyo 1608402, Japan
[4] Tokyo Med Univ, Div Thorac Surg, Ibaraki Med Ctr, Tokyo 1608402, Japan
[5] Univ Colorado Denver, Div Med Oncol & Pathol, Denver, CO USA
关键词
AQUA; immunohistochemistry; IGF-1R; Predictive marker;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:S449 / S450
页数:2
相关论文
共 50 条
  • [31] Primary TKI resistance in advanced non-small cell lung cancer with EGFR mutation: an open question
    Giuliani, Jacopo
    Martelli, Salvatore
    Remo, Andrea
    Bonetti, Andrea
    TUMORI, 2015, 101 (04) : E115 - E117
  • [32] Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer
    Zhimin Zhang
    Xiaojuan Lian
    Wei Xie
    Jin Quan
    Maojun Liao
    Yan Wu
    Zhen-Zhou Yang
    Ge Wang
    Scientific Reports, 10
  • [33] Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer
    Zhang, Zhimin
    Lian, Xiaojuan
    Xie, Wei
    Quan, Jin
    Liao, Maojun
    Wu, Yan
    Yang, Zhen-Zhou
    Wang, Ge
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [34] EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
    Kobayashi, S
    Boggon, TJ
    Dayaram, T
    Janne, PA
    Kocher, O
    Meyerson, M
    Johnson, BE
    Eck, MJ
    Tenen, DG
    Halmos, B
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (08): : 786 - 792
  • [35] CLINICAL SIGNIFICANCE OF IGF-1R AND MMP-7 EXPRESSION IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
    Yamamoto, Taketsugu
    Oshima, Takashi
    Yoshihara, Kazue
    Nishii, Teppei
    Arai, Hiromasa
    Inui, Kenji
    Adachi, Hiroyuki
    Rino, Yasushi
    Masuda, Munetaka
    Imada, Toshio
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S968 - S969
  • [36] Utility of a novel quantitative EGFR-mutated protein analysis using AQUA system for EGFR-TKI treatment in non-small cell lung cancer
    Goto, Koichi
    Ishii, Genichiro
    Fujimoto-Ouchi, Kaori
    Shirane, Masatoshi
    Saito, Tatsuro
    Nishiwaki, Morie
    Ohmatsu, Hironobu
    Niho, Seiji
    Yoh, Kiyotaka
    Umemura, Shigeki
    Yamane, Yuki
    Shiozawa, Toshihiro
    Yamaguchi, Yoko
    Taira, Tetsuhiko
    Nagai, Kanji
    Ohe, Yuichiro
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [37] UTILITY OF A NOVEL QUANTITATIVE EGFR MUTATED PROTEIN ANALYSIS USING AQUA SYSTEM FOR EGFR-TKI TREATMENT IN NON-SMALL CELL LUNG CANCER PATIENTS
    Goto, K.
    Ishii, G.
    Fujimoto-Ouchi, K.
    Shirane, M.
    Ohmatsu, H.
    Niho, S.
    Yoh, K.
    Umemura, S.
    Nagai, K.
    Ohe, Y.
    ANNALS OF ONCOLOGY, 2012, 23 : 534 - 534
  • [38] Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib
    Costa, Daniel B.
    Nguyen, Kim-Son H.
    Cho, Young C.
    Sequist, Lecia V.
    Jackman, David M.
    Riely, GregoryJ.
    Yeap, Beow Y.
    Halmos, Balazs
    Kim, Joo H.
    Jaenne, Pasi A.
    Huberman, Mark S.
    Pao, William
    Tenen, Daniel G.
    Kobayashi, Susumu
    CLINICAL CANCER RESEARCH, 2008, 14 (21) : 7060 - 7067
  • [39] Long non-coding RNAs in non-small cell lung cancer: implications for EGFR-TKI resistance
    Liu, Detian
    Lu, Xiaolin
    Huang, Wentao
    Zhuang, Wei
    FRONTIERS IN GENETICS, 2023, 14
  • [40] Immune microenvironment change after acquiring resistance to EGFR TKI therapy in EGFR mutant non-small cell lung cancer
    Kim, Tae-Jung
    Kang, Jin-Hyoung
    Hong, Sook-hee
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)